Pfizer yanks sickle-cell treatment worldwide after possible link to deaths

The benefits of Oxbryta no longer outweigh the risks, Pfizer says.

Previous post Dollar General asks shareholders to reject investment firm’s stock-purchase offer
Next post Vistra’s stock is up more than 200% this year. Could more gains could be ahead?